ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 27c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q4 EPS of ($0.96), $0.27 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS